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ABSTRACT. To investigate further the role of the hypothalamic luteinizing hormone releasing factor (LRF) pulse generator and the pituitary L R F receptor in the regulation of gonadotropin secretion and gonadal steroidogenesis in the ovine (0) fetus and neonatal lamb, we measured the increment (the difference between the concentration of plasma L H at time 0 and peak L H ) in o L H (AoLH) and oFSH (AoFSH) responses to a potent L R F agonist, D -T~~~P~O~N E~-L R F (LRF-A), after consecutive daily doses in 17 ovine fetuses (six females, 11 males) and in 15 neonatal lambs (six females, nine males). Seven of the lambs had been studied a s fetuses. In addition, plasma concentrations of testosterone (T) and androstenedione (A4A) were measured in nine male fetuses. After a stimulatory response to the first dose of LRF-A, the mean AoLH and AoFSH responses in the 106-to 118-d gestation fetuses of both sexes were significantly suppressed by the fourth dose and in the neonatal lamb by the second dose. Suppression was sustained throughout the duration of LRF-A therapy which included the gestational interval when the fetal pituitary exhibits its greatest responsiveness to an acute dose of synthetic LRF. The duration of oLH and oFSH suppression after cessation of LRF-A therapy was studied by measuring the AoLH and AoFSH responses to L R F before and at intervals after LRF-A therapy. In the fetus, the AoLH and AoFSH responses remained significantly decreased 7-8 d after the agonist was discontinued. No statistical differences were detected in the AoLH and AoFSH responses to L R F in the neonatal lamb at least by the 4th d after discontinuation of LRF-A. Increasing the duration of LRF-A therapy did not prolong the length of recovery of L H and F S H responsiveness to L R F in either fetus or neonate. Mean fetal plasma T levels rose significantly in response to a single dose of LRF or LRF-A. Peak T responses to single dose L R F or LRF-A were lower on d 2-4 and d 7 than on the 1st d of LRF-A administration. These changes coincided with the decrease in the release of o L H and oFSH. Peak T responses to a single dose of LRF or LRF-A had not returned to pretreatment levels by d 1-5 after discontinuation of chronic LRF-A administration in the male fetus. Plasma A4A concentrations were not affected by chronic exposure to LRF-A. The results show that secretion of F S H and L H in the midgestation fetus is LRF-dependent. The induction of L R F desensitization in the fetal gonadotrope suggests that pulsatile gonadotropin secretion in the fetus is a consequence of pulsatile release of LRF. A relatively delayed recovery of L H and F S H responsiveness in the fetus may be due to a functional immaturity of the gonadotropes and their capacity to recover from desensitization, including down-regulation of LRF receptors. The increase in the concentration of testosterone after the administration of LRF is evidence of the bioactivity of fetal oLH. (Pediatv Res 25:347-352,  1989) Abbreviations oLH, ovine luteinizing hormone oFSH, ovine follicle-stimulating hormone T, testosterone A4A, androstenedione LRF, luteinizing hormone releasing factor LRF-A, luteinizing hormone releasing factor agonist (DTrp6Pro9NEt-LRF) DHEA, dehydroepiandrosterone IV, intravenous Chronic administration of potent LRF-A, similar to continuous infusion of native LRF results, after initial stimulation of gonadotropin release, in desensitization of pituitary gonadotropes and suppression of gonadotropin secretion in experimental animals (1-1 I), adults (12) and children (1 3-1 5). However, nothing is known about the effect of chronic administration of LRF-A on pituitary-gonadal function in the fetus.
We previously reported that in the ovine fetus the plasma concentrations of oLH and oFSH rise to peak levels by midgestation and decline to low levels by term (16) . The ovine hypothalamus contains immunoreactive LRF as early as 58 d of gestation (Styne DL, Gluckman PD, Kaplan SL, Grumbach MM, unpublished data). Further, the ovine fetal pituitary gland has the capacity to respond to exogenous LRF; the maximal increment in oLH occurs during midgestation when the mean 348 CLARK gonadotropin concentrations are highest (1 7). These studies indicate that LRF receptors are present and functional in the fetal pituitary gland by midgestation, and that a readily releasable store of gonadotropins is present. Moreover, pulsatile LH secretion occurs in the fetus as early as 81 d of gestation (18) . We postulated that at least by midgestation, LH and FSH secretion is not autonomous but rather it is dependent upon pulsatile LRF secretion by the fetal hypothalamic LRF pulse generator (I 8).
To characterize further the hypothalamic-pituitary gonadotropin apparatus in vivo in the fetus and neonatal lamb, we questioned whether chronic administration of a potent LRF-A would induce desensitization of fetal pituitary gonadotropes and suppression of gonadotropin secretion and if so, whether there was a difference in the response of the fetus and neonatal lamb; of special interest was the opportunity to determine whether fetal gonadotropin secretion in midgestation was LRF-dependent and also to assess the role of fetal hypothalamic LRF in the pulsatile release of LH and FSH in the fetus. Because of technical factors, it has not been possible to sample hypophyseal-portal venous blood or hypothalamic interstitial fluid in the fetus in vivo for LRF pulsatility.
In addition, we studied the changes in plasma T and androstenedione (A4A) in the male fetus to determine whether the desensitization of the fetal gonadotrope by chronic intermittent LRF-A administration is accompanied by a decrease in fetal testicular steroidogenesis.
MATERIALS AND METHODS

Animals and Experimental Procedz~res.
Ewes of mixed Western breeding who were mated on a single occasion were used in these studies. Gestation in these animals is 147 +. 3 d. During our study, the ewes were maintained indoors with the same fixed lighting each day (from 0600 to 1900). After spinal anesthesia, catheters were placed in a maternal dorsalis pedis vein and artery. Hysterotomy was performed, as described previously (19) , and the fetal neck exposed without removing the head from the utcrus. Using local anesthesia, polyvinyl catheters were inserted into one carotid artery and one jugular vein. The uterus was then closed and catheters were externalized through a stab incision in thc maternal flank. All studies were begun at least 48 h after surgery and were performed with the ewe standing quietly in a study cage. Fetal blood samples were obtained from the arterial catheter every 15 rnin for a maximum of 3 h; LRF or LRF-A was infused into the venous catheter. Only fetuses with normal arterial blood gases (pH 2 7.33 and POz 2 18 torr) were used in these studies.
The neonatal lambs were maintained indoors in cages with their mothers. All the lambs were fed by their mothers and were healthy and gaining wt normally. At 24-48 h before the study, catheters were placed in the dorsalis pedis vein and artery using local anesthesia. All studies were performed with the lambs in a sling in close proximity to their mothers. LRF or LRF-A was administered IV, and blood samples were obtained from the arterial catheter every 15 min for 3 h.
Rxp:pcrimmfal Grozlps. Both fetuses and neonates were studied as follows: The increment in LH (ALH) and FSH (AFSH) is defined as the difference between LH and FSH at time 0 and the peak response. To evaluate the AoLH and AoFSH responses to LRF-A, a 10-pg bolus was given daily for 2-7 consecutive d in the fetus and for 2-14 consecutive d in the neonate. To assess the recovery of pituitary LH and FSH secretion after LRF-A treatment, the response to synthetic LRF after treatment with LRF-A was compared to the response to LRF before treatment with LRF-A. All animals were given LRF 5 pg IV 1-6 d before LRF-A was administered (preagonist) and again at intervals of 1-4 d for a total of 10-1 1 d after the last dose of LRF-A (postagonist). Samples were obtained every 15 rnin for LH and every 30 rnin for FSH for I h before and 2 h after LRF-A or LRF were given.
Fetuses. Seventeen fetuses (six females and 11 males) were studied beginning at 106-1 18 d of gestation. The fetuses were divided into three groups, all of whom received LRF-A as a 10-pg daily IV bolus for 2 d (one female and three males), 4 d (three females and three males), and 7 d (two females and five males). The postagonist LRF tests (5 pg IV) were stared at 1 15-129 d of gestational age and completed at 123-132 d of gestational age.
In addition to the gonadotropin response, the T and A4A responses to LRF-A treatment were tested in nine of the male fetuses. Plasma from the samples taken 15 min before and immediately before LRF-A or LRF administration and from the samples obtained at 60 and 45 min before LRF-A or LRF were pooled and assayed for T and A4A. The results of these two pooled plasma samples were averaged to give one baseline value. Similarly, plasma from the samples obtained at 45 and 60 min after LRF-A or LRF administration were pooled and assayed for T and AqA concentrations to estimate the peak value.
Neonates. Fifteen neonatal lambs (six females and nine males) were studied at 9-17 d of age. Seven of the lambs (three females and four males) had previously been studied as fetuses. The neonatal lambs were divided into five groups with three lambs in each group. There were two males and one female in each group of lambs except the group given LRF-A for 4 d, in which there were two females and one male. The fifth group of three lambs (one female and two males) received LRF-A 4 pg/kg dose for 7 consecutive d; the other four groups were given 10 pg/d of LRF-A. The postagonist LRF tests (5 pg IV) were started at 19-35 d of age and completed at 24-41 d of age.
Hormone assay. Gonudotrop~ns. Plasma oLH and oFSH were determined by homologous RIA and double antibody separation, as previously described (16) . The sensitivity of the oLH assay was 0.01 ng and the half-maximal displacement value was 0.05 ng. The within-assay coefficient of variation was 4.7%, and the interassay coefficient of variation was 15.3%. Cross-reaction with oFSH was 1.8% and with ovine a-glycoprotein hormone subunit was less than 1%. Values are expressed in terms of a highly purified oLH standard (Gi 256 DA), obtained from Dr. Harold Papkoff (University of California, San Francisco) which has an immunopotency 2.8 times that of NIH-LH-S 18 and a biopotency 2.75 times that of NIH-LH-S 1. The sensitivity of the oFSH assay was 0.03 ng, and the half-maximal displacement value was 0.45 ng. The within-assay coefficient of variation was 7%, and the interassay coefficient of variation was 1 1.2%. Cross-reaction with oLH and the ovine a-glycoprotein hormone subunit was less than I %. oFSH values are expressed in terms of oFSH standard Gq 21 1 BP (Papkoff) which has an immunopotency 17 times that of NIH-FSH-S12 and a biopotency 60 times that of NIH-FSH-S 1.
Steroids. Tritiated [ 1 ,z3H(N)], AqA (4 1.0 Ci . mmol-I), and [10,2P3H(N) T (50.4 Ci.mmo1-l) were purchased from New England Nuclear Corp., Boston, MA. The radioactive steroids were purified by Celite chromatography before use (20) . Nonradioactive steroids were obtained from Mann Research Laboratories, Inc., New York, NY. Antisera to T and AqA were purchased from Optimox, Inc., Palos Verdes Peninsula, CA. T antiserum had a cross-reactivity of 1 % for A4A. Cross-reactivity of the AqA antiserum for T was 0.1 %.
Evaluation of steroid assay specificity: A modification of the chromatography system was tested using tritium-labeled steroids. When applied to a Celite microcolumn with an ethylene glycol stationary phase, 97.5% of labeled A4A eluted in the least polar fraction (mobile phase: 100% isooctane, 3.5 mL). A total of 90.1 % of labeled DHEA eluted in the fraction of medium polarity (7% ethyl acetate in isooctane, 3.5 mL), and 96.1 % of labeled T was recovered in the most polar fraction (15% ethyl acetate in isooctane, 5 mL). The A4A fraction and the fraction containing T were used.
Specificity of the steroid assays for use with fetal ovinc plasma was assessed by cochromatography as previously described (2 1, 22) . 6000 dpm ['HI A4A and [3H] T were added to 2 mL pooled EFFECT O F LRF AGONIST ON FETUS A N D NEONATE 349 fetal ovine plasma from samples obtained in the basal state and during LRF stimulation. The dried ether extract was applied to a Celite column and eluted using the above described mobile phases. Fractions of 0.5 mL were collected for each mobile phase, and one-half of each fraction was counted to assess the amount of labeled steroid present. The other half was dried under nitrogen, and the amount of immunoreactive steroid in the residue was measured by RIA. The cochromatographic elution pattern for labeled and immunoreactive A4A and T were congruent. In agreement with previous observations (23), we found an immunoreactive peak in the last 0.5 mL of the T fraction that also cross-reacted with the A4A antiserum. These unknown crossreactants were eliminated from the T fraction by excluding the last 0.5 ml of all the eluants of the T fraction.
Steroid RIA: 2000 dpm ['HI A4A and ['HI T were added to the fetal sheep samples to allow for correction of procedural losses. After ether extraction and chromatography, the dried residucs of the 100% isooctane fraction were assayed for immunoreactive A4A, and the 15% ethyl acetate/isooctane fraction was assayed for T immunoreactivity, as previously described (20) .
The sensitivity of the assay expressed as the minimum detectable amount of steroidltube was 5.8 pg A4A and 6.7 pg T, respectively. Combined intraassay and interassay variability were calculated according to the method of Rodbard (24) . Intraassay coefficient of variation in the AaA assay was 9.1 % (low concentration range 22.8-37.2 ng/dL) and 10.8% (high concentration range 86.8-134.1 ng/dL); the AaA interassay coefficient of variation was 12.9% and 6.4%, respectively. Intraassay variability in the T assay was 6.6% (medium concentration range 60.6-70.5 ng/dL) and 8.0% (high concentration range 242.7-280.3 ng/dL); interassay variability was 6.5% for both concentration ranges.
LRF agonist: The potent LRF agonist LRF-A was kindly provided by Dr. Jean Rivier and Dr. Wylie Vale (The Salk Institute, La Jolla, CA). The potent LRF-A was selected because it binds to high affinity LRF receptors and can be given once/d.
Statistical analysis. The Wilcoxon signed rank test was used to compare the incremental response in gonadotropin (AoLH and AoFSH) and steroid (T, A4A) levels during LRF-A treatment and the preagonist and postagonist responses to LRF testing. A p value of 5 0.05 is significant.
The gonadotropin responses in the three groups of fetuses and five groups of neonates were first compared using the KruskalWallis test. The gonadotropin responses between groups were compared on d 1, 4, and 7 of LRF-A treatment in the fetuses and d 1, 4, 7, and 14 in the neonatal lambs. In addition, the gonadotropin responses to the preagonist dose of LRF and those on d 3-4, 7-8 and 10-1 1 postagonist were compared between groups. As significant differences in the gonadotropin responses during LRF-A treatment or recovery were not detected between animals treated for different lengths of time or with differentlkg doses, treatment and recovery data for these groups were pooled. The I-way ANOVA was used to compare the fetal and neonatal gonadotropin responses to LRF-A. Regression analysis was used to determine if there was a correlation between the response to LRF and the response to LRF-A. The differences between males and females were analyzed by the t test. The gonadotropin response to the initial dose of LRF and LRF-A in the animals studied before and after birth was analyzed by the paired t test.
Steroid data were tested for deviation from the normal distribution by graphic methods using the normal probability scale (25) . When normalization could be achieved by logarithmic transformation, the paired t test was used on the log transformed data; otherwise, the Wilcoxon paired-sample test was applied. All male fetuses responded to each dose of LRF or LRF-A with a significant rise of plasma T above the basal level ( p < the first dose of LRF-A was not different from the T response to There was no significant difference between males and females native LRF. Peak T responses on either the 2nd or the 4th d of in the gonadotropin responses to the preagonist d of LRF and LRF-A administration were lower than the response to the first the first dose of LRF-A in either fetuses or lambs.
dose of LRF-A ( p < 0.05). Lower peak responses were mainFinally, seven animals were studied both as fetuses and neotained on the 7th d of LRF-A treatment (versus d 1 of LRF-A p nates. There were no differences between fetuses and neonates < 0.05). The basal and peak levels of A4A were similar before in the gonadotropin responses to the preagonist dose of LRF or (2 1.9 k 5.0 ng/dL) and during chronic LRF-A treatment (25.7 the first dose of LRF-A.
In the fetuses and neonatal lambs, comparisons were made DISCUSSION between the plasma LH and FSH responses to LRF before the administration of LRF-A and during recovery from desensitizaSuppression of pituitary gonadotropes by consecutive daily tion by LRF-A after the discontinuation of the daily injections. doses of LRF-A was induced in the fetus and neonatal lamb. As long as 7-8 d after discontinuation of LRF-A, the mean After a stimulatory response to the first dose, striking suppression AoLH and oFSH concentrations in the fetuses were significantly of the oLH and oFSH responses to LRF-A occurred by the fourth less than during the preagonist period (LH p < 0.005, FSH p < daily dose in the fetus and by the second daily dose in the lamb. Table I ). By 10-1 1 d, the mean fetal AoLH and AoFSH In the male fetus, a significant decrease in peak T concentrations were similar to the responses before LRF-A administration. In was observed concomitantly. contrast to the fetus, the AoLH and AoFSH responses to LRF in
0.01) (
The decrease in gonadotropin release was sustained throughout the neonates by d 3 to 4 after discontinuation of LRF-A were the duration of LRF-A administration. The oLH responses to not significantly different than the responses to LRF preagonist LRF remained suppressed after discontinuation of LRF-A for ( Table 1) .
about 7-8 d in the fetus but not in the neonate. In the fetus, the No significant differences were detected in the A gonadotropin postagonist LRF stimulation tests were performed before 132 d responses to LRF or LRF-A treatment or during recovery be-of gestational age as previous studies in our laboratory ( (17) . The contribution of steroidogenic sites other than the fetal testes to circulating fetal plasma T is uncertain. During this period of gestation, T levels are higher in the male than in the female (26, 27) . In an earlier study (27) , a decrease in testicular T content was noted towards late gestation, a stage when plasma T rises in the male ovine fetus. Our data show an increase in the concentration of plasma T after acute administration of LRF and the first dose of LRF-A. The rise in T after native LRF and the first dose of LRF-A coincides with the rise in plasma LH and FSH, suggesting a bioactive LH-dependent response and a gonadal source for the circulating T. These observations support a functioning hypothalamic-pituitary-gonadal axis in the ovine fetus. By contrast, although the LH and FSH responses to LRF-A in the ovine fetuses almost disappear during LRF-A treatment, the basal T shows only a trend to lower concentrations. These results are most likely explained by residual basal bioactive LH secretion by the desensitized pituitary gonadotrope, by persistence of an LH effect on the fetal testes, or by a low amplitude pulse of LH evoked by the acute injection of LRF-A as a result of incomplete receptor blockade.
We documented the first decrease in the T response to LRF during d 2-4 of LRF-A treatment, coinciding with the decrease in the LH response. This observation supports the concept of desensitization of the fetal gonadotrope to LRF, followed by decreased LH stimulation of the testes (28-3 1). The observation that the T response to LRF administration did not return to preagonist levels by d 1-5 posttreatment is consistent with a reverse pattern of reactivation of the pituitary-gonadal axis after LRF-A treatment. A similar pattern is found in rams (8) and in children treated for true or central precocious puberty (14) . We did not observe an inhibitory effect of chronic LRF-A administration on plasma A4A concentrations.
The most potent LRF agonists have substitutions of a ~-a m i n 0 acid in position six and substitution of the glycine amide in the tenth position by ethylamide (10) . D-T~~OP~O'NE~-LRF is 140 times more potent than LRF and initially produces a striking elevation of plasma LH (32) (33) (34) (35) . The LRF analogs bind to high affinity receptors on the gonadotrope plasma membrane. Chronic administration of LRF agonist (in contrast to an acute dose) produces paradoxical desensitization of pituitary gonadotropes in animals and man (1-15) with suppression of gonadotropin secretion. This phenomenon has been associated with a decrease in receptor number (4, 33, 34, 35) , but other poorly understood postreceptor mechanisms contribute to the decrease in gonadotropin secretion.
The present study provides evidence that specific LRF receptors are present in the sheep fetus by midgestation and that the fetal gonadotrope exhibits desensitization in response to the repeated daily administration of a potent LRF agonist. The desensitization of LRF receptors on the gonadotrope as evidenced by the suppression of the gonadotropin response by an LRF agonist is compelling circumstantial evidence for LRF secretion early in gestation. Previously, we demonstrated that the ovine fetus secreted LH and FSH in a pulsatile manner (18) ; the results of the present study would indicate that the fetal LRF pulse generator is operative at least by midgestation and the pulsatile release of hypothalamic LRF evokes the pulsatile LH secretion in the fetus.
In addition, this study supports a maturational change in the gonadotrope as demonstrated by the greater suppression of LH and FSH in the fetus than in the neonate during LRF-A treatment and by the more persistent suppression of LH and FSH secretion postagonist treatment in the fetus than in the neonate.
The decrease in T response to LRF-A is most likely secondary to the suppression of gonadotropin secretion by LRF-A. The timing of the changes in gonadotropin responses and in T in the male fetus makes a direct inhibitory effect of LRF-A on fetal steroid biosynthesis unlikely.
